COMPASS Pathways (CMPS) News Today → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free CMPS Stock Alerts $8.13 -0.15 (-1.81%) (As of 03:39 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 3:54 AM | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for COMPASS Pathways (NASDAQ:CMPS)May 13 at 12:23 PM | finance.yahoo.comCOMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call TranscriptMay 13 at 8:47 AM | marketbeat.comCOMPASS Pathways (NASDAQ:CMPS) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $120.00 price objective on shares of COMPASS Pathways in a research report on Monday.May 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for COMPASS Pathways Amid Strong Financials and Promising Clinical TrialsMay 9, 2024 | fool.comCompass Pathways Plc (CMPS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | msn.comCMPS Stock Earnings: Compass Pathways Misses EPS for Q1 2024May 8, 2024 | globenewswire.comCompass Pathways Announces First Quarter 2024 Financial Results and Business HighlightsMay 8, 2024 | globenewswire.comCompass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorderMay 7, 2024 | insidertrades.comCOMPASS Pathways plc (NASDAQ:CMPS) Major Shareholder George Jay Goldsmith Sells 9,621 SharesMay 6, 2024 | marketbeat.comInsider Selling: COMPASS Pathways plc (NASDAQ:CMPS) Major Shareholder Sells 9,621 Shares of StockCOMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) major shareholder George Jay Goldsmith sold 9,621 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $8.29, for a total transaction of $79,758.09. Following the transaction, the insider now owns 3,966,052 shares in the company, valued at approximately $32,878,571.08. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.May 6, 2024 | marketbeat.comCOMPASS Pathways (CMPS) Set to Announce Quarterly Earnings on WednesdayCOMPASS Pathways (NASDAQ:CMPS) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.May 3, 2024 | globenewswire.comCompass Pathways to announce first quarter financial results on May 8, 2024May 2, 2024 | globenewswire.comCompass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatmentApril 30, 2024 | marketbeat.comCOMPASS Pathways (NASDAQ:CMPS) Trading 5.4% Higher COMPASS Pathways (NASDAQ:CMPS) Trading 5.4% HigherApril 30, 2024 | marketbeat.comCOMPASS Pathways (NASDAQ:CMPS) Rating Reiterated by Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating on shares of COMPASS Pathways in a report on Tuesday.April 29, 2024 | globenewswire.comCompass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depressionApril 25, 2024 | seekingalpha.comCOMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?April 20, 2024 | benzinga.comCompass Pathways Stock (NASDAQ:CMPS), Analyst Ratings, Price Targets, PredictionsApril 19, 2024 | insidertrades.comCOMPASS Pathways plc (NASDAQ:CMPS) Major Shareholder George Jay Goldsmith Sells 23,881 SharesApril 18, 2024 | marketbeat.comCOMPASS Pathways plc (NASDAQ:CMPS) Major Shareholder Sells $203,704.93 in StockCOMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) major shareholder George Jay Goldsmith sold 23,881 shares of the firm's stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $8.53, for a total value of $203,704.93. Following the completion of the transaction, the insider now owns 3,986,523 shares in the company, valued at $34,005,041.19. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.April 18, 2024 | marketbeat.comCOMPASS Pathways' (CMPS) "Overweight" Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating on shares of COMPASS Pathways in a report on Thursday.April 16, 2024 | marketbeat.comCOMPASS Pathways (NASDAQ:CMPS) Trading 4.6% Higher COMPASS Pathways (NASDAQ:CMPS) Shares Up 4.6%April 9, 2024 | marketbeat.comCOMPASS Pathways (NASDAQ:CMPS) Shares Gap Down to $9.74COMPASS Pathways (NASDAQ:CMPS) Shares Gap Down to $9.74April 5, 2024 | marketbeat.comCOMPASS Pathways (NASDAQ:CMPS) Shares Down 3.6% COMPASS Pathways (NASDAQ:CMPS) Trading Down 3.6%April 4, 2024 | marketbeat.comCOMPASS Pathways (NASDAQ:CMPS) Trading 5.6% Higher COMPASS Pathways (NASDAQ:CMPS) Stock Price Up 5.6%April 4, 2024 | investing.comCompass Pathways insider sells over $460k in sharesApril 3, 2024 | insidertrades.comInsider Selling: COMPASS Pathways plc (NASDAQ:CMPS) Major Shareholder Sells 25,750 Shares of StockApril 1, 2024 | globenewswire.comCompass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | marketbeat.comCOMPASS Pathways (NASDAQ:CMPS) Shares Gap Up to $8.32COMPASS Pathways (NASDAQ:CMPS) Shares Gap Up to $8.32April 1, 2024 | markets.businessinsider.comBuy Rating on COMPASS Pathways: COMP360’s Market Potential and Promising TRD TherapyApril 1, 2024 | marketbeat.comCOMPASS Pathways plc (NASDAQ:CMPS) Major Shareholder Ekaterina Malievskaia Sells 25,750 SharesCOMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) major shareholder Ekaterina Malievskaia sold 25,750 shares of the company's stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $8.65, for a total value of $222,737.50. Following the completion of the transaction, the insider now directly owns 4,036,154 shares of the company's stock, valued at approximately $34,912,732.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.April 1, 2024 | marketbeat.comCOMPASS Pathways (NASDAQ:CMPS) Coverage Initiated at Morgan StanleyMorgan Stanley began coverage on shares of COMPASS Pathways in a research note on Monday. They set an "overweight" rating and a $30.00 price target on the stock.April 1, 2024 | marketbeat.comCOMPASS Pathways plc (NASDAQ:CMPS) Receives Consensus Rating of "Buy" from BrokeragesShares of COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) have received a consensus rating of "Buy" from the five research firms that are covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12-month targMarch 31, 2024 | finance.yahoo.com20 Most Depressed Countries in AsiaMarch 30, 2024 | marketbeat.comCOMPASS Pathways plc (NASDAQ:CMPS) Sees Large Decrease in Short InterestCOMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) was the target of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 3,150,000 shares, a drop of 15.8% from the February 29th total of 3,740,000 shares. Based on an average trading volume of 680,400 shares, the short-interest ratio is currently 4.6 days.March 30, 2024 | uk.investing.comCompass Pathways co-founders step down from boardMarch 28, 2024 | marketbeat.comCOMPASS Pathways (NASDAQ:CMPS) Sees Large Volume IncreaseCOMPASS Pathways (NASDAQ:CMPS) Sees Unusually-High Trading VolumeMarch 28, 2024 | globenewswire.comCompass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of DirectorsMarch 28, 2024 | marketbeat.comCOMPASS Pathways plc (NASDAQ:CMPS) Shares Bought by ARK Investment Management LLCARK Investment Management LLC raised its holdings in COMPASS Pathways plc (NASDAQ:CMPS - Free Report) by 7.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,618,871 shares of the company's stock after purchasing anMarch 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for COMPASS Pathways Amid Promising Neuropsychiatric Treatment AdvancesMarch 16, 2024 | investing.comCompass Pathways director sells over $700k in company sharesMarch 15, 2024 | insidertrades.comCOMPASS Pathways plc (NASDAQ:CMPS) Director Sells $166,529.20 in StockMarch 14, 2024 | marketbeat.comCOMPASS Pathways (NASDAQ:CMPS) Stock Price Down 8.4%COMPASS Pathways (NASDAQ:CMPS) Shares Down 8.4%March 7, 2024 | marketbeat.comBrokers Set Expectations for COMPASS Pathways plc's FY2024 Earnings (NASDAQ:CMPS)COMPASS Pathways plc (NASDAQ:CMPS - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of COMPASS Pathways in a report issued on Monday, March 4th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings of ($2.47)March 5, 2024 | fool.com3 Biopharma Stocks You Don't Want to Miss in the New Bull MarketMarch 3, 2024 | marketbeat.comArmistice Capital LLC Acquires New Stake in COMPASS Pathways plc (NASDAQ:CMPS)Armistice Capital LLC acquired a new stake in COMPASS Pathways plc (NASDAQ:CMPS - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 400,000 shares of the company's stock, valued at approximately $2,960,000. Armistice Capital LLC owned approMarch 1, 2024 | marketbeat.comCOMPASS Pathways (NASDAQ:CMPS) Stock Price Up 11.6%COMPASS Pathways (NASDAQ:CMPS) Stock Price Up 11.6%March 1, 2024 | marketbeat.comCOMPASS Pathways' (CMPS) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $120.00 price objective on shares of COMPASS Pathways in a report on Friday.March 1, 2024 | finance.yahoo.comCOMPASS Pathways plc (NASDAQ:CMPS) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | marketwatch.comCompass Pathways Shares Tumble 18% After Warning of Trial Delay Get COMPASS Pathways News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump Reveals Conspiracy Behind Fed-Controlled Digital Currency. (Ad)Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it. This means you must act NOW before it's too late. CMPS Media Mentions By Week CMPS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMPS News Sentiment▼0.260.55▲Average Medical News Sentiment CMPS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMPS Articles This Week▼62▲CMPS Articles Average Week Get COMPASS Pathways News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ABUS News Today LRMR News Today VERV News Today ALT News Today KALV News Today TVTX News Today OCS News Today STTK News Today ATXS News Today APLT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMPS) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
